Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I've been adding over last 2 days just in case the company is legit. If they can do some of what they are saying Valuation will go higher that 1.6. If not oh well!
On the bright side we were under a penny about 2 weeks ago!
Crazy Pot ETF up 10% on Coke news having a cbd infused drink. I don't own enough of that.
So I looked up Coventry supposed investments. They don't seem to being to be doing very well on companys mentioned.
Gold Lakes Corp (GLLK) MATERIALS 130,000,010 1,300,000.10 1 13G 2017-04-03
Nutra Pharma Corp (NPHC) HEALTH CARE 182,208,668 182,208.67 2 13G 2018-02-05
SANOMEDICS INC (SIMH) HEALTH CARE 737 368.50 3 13G 2014-10-23
PROPANC BIOPHARMA IN (PPCB) 12,500,010 5 13G 2018-09-06
Nice start to the day!
That would have been a terrible trading strategy on a thinly traded stock!
Well, so far I've sold 60K of the 120K I had. My average sell on the 60K was .14, cost .02 also sold some to early. I now have 60,000 with a average cost of .005. Not perfect but I made some $$$ will hold on to these shares now and see if some funding for trials materializes. If not my cost basis is $300.00
Well he predicted today.
Your .06 prediction because of the chart looking pretty doubtful at this point.
Yes, maybe this is the break through on PPS we've been looking for? Nice volume too!
I've been buying little by little this summer. Got cost basis down to .033. That seems achievable in the short term plus much more.
All time low on a day when CEO is quoted in forbes.
Someone is dumping their shares. Can't understand why?
Phase 3 trials have not started correct? What would you anticipate the next news being. That they have funding so they can begin?
Additionally, Power Up has the option to convert all or any amount of the principal face amount of the March 2018 Power Up Note, starting on September 1, 2018
Interesting 9/1 is Saturday so first trading day is Tuesday the 4th where they can convert.
I agree with this statement. Why do you think revenue from Africa is not coming anytime soon Buddylou. I do agree that I've been somewhat concerned that Africa seems to have been put on the back burner and focus of latest press releases has been all based on FDA and Cyctocom. Is this revenue story still years away?
In some ways I agree. I feel like I can't give up now but I had been starting to lose hope in Africa especially after the weird press release with no mention of the Fidson distribution agreement then the re-submission. Press releases of new inexpensive ARV's being release in Africa. Has LDN's time gone and past? I don't believe so but approvals have taken so long. The new chairman of board announcement was encouraging plus the eventual phase 3 trials for Chrohn's in USA we have 10%. At least they are doing better with giving us press releases, facebook posts, makes me hope better news might be coming as far as revenue announcements but this has been a frustrating investment so far.
IMUN is posting on their facebook page their latest press releases. First posts in more than 2 years.
Noreen will be presenting in Vegas December at HIV conference. Maybe the company is finally starting a PR campaign to the word out. Now we need actual sales and revenue.
Would be nice if they could share the news of NACA approval during the conference!
Your CD4 count will go way down when you're having chemotherapy for cancer.
Can you imagine if everyone who has to go through chemo is prescribed LDN to boost up their CD4 count?
This is kind of the synopsis here. They are looking to get LDN approved as an adjunct therapy not a stand alone?
Given these robust results, LodonalTM should be considered as an adjunct immune therapy with standard antiretroviral therapy given its proven potential to maintain or increase CD4 count levels, which suggest an increase or stabilization of patient’s immunity that can potentially prevent opportunistic infections.
LodonalTM can serve as a preventative therapy, alleviating treatment requirements that cannot be met due to a lack of medical infrastructure in oncological treatment. !
It seems like they have been able to get lenders through convertible notes as recently as this month from 8k's. Not for large amounts though,
Someone selling 548K at .0198. I guess they don't believe Nigeria revenues are coming?
Whats the hold up?
In September of 2017 IMUN/AHAR filed our application for the approval of Lodonal with NACA. NACA approval would provide the opportunity for purchases of Lodonal for HIV patients through the agency. The NACA regulatory paperwork is now under review and the Company hopes to have approval by Q1 of 2018.
No dilution! They are funding operations in other ways?
I agree with 20% ownership I would be adding a lot more to my position, but who knows because of bad press releases that create more questions than answers.
:) Hopeful knew about the misprint before anyone else. I'm happy he clarified that.
I am a direct owner of Cytocom shares. Not many, I received them from the spinoff. Does IMUN own an additional 10% of Cytocom from this press release, or 10% total? Does anyone know as that is a difference maker. Do we own close to 20% or 10%?
Ok this is much better. Hopeful was right! It was a misprint. A big misprint but now corrected!
I get that there are positives but I feel they have always been there as a long term story. As Buddylou mentioned the only new news is the pet story which I'm sure is in beginning stages. In the short term I was hoping for revenues from Africa. That to me is now in doubt and being briefly mentioned in the press release. A new antiretroviral cocktail is being introduced in Africa that could effect the distribution of LDN?? Again all speculation and maybe there still is potential in Africa. They just talked about an agreement with Fidson in 8k. Just seems like this press release didn't address the Nigeria story in a very positive way.
What is a misprint?
With no marketing partner. What does that mean? Hopeful will result in sales in next coming months? I would say the news on Nigeria and Africa in general is not that positive. Hopefully things are still ok and this move to news on Cytocom is not re-focusing efforts.
Sounds like Noreen is moving over to Cytocom from IMUN
Sounds good. I'm glad to hear IMUN has advantages which I kind of figured it did. Think I'm just getting paranoid with the lack of news. Although the recent Fidson announcement in 8k sounds very promising that things are moving forward.
Ok, just started finding a lot of articles like these from end 2017. Organizations like WHO seem pretty excited about the transition.
http://www.who.int/hiv/mediacentre/news/dolutegravir-icasa2017/en/
Is this inexpensive new drug cocktail anything to be concerned about? It looks like most countries will be switching over to it in 2018. I've been long IMUN forever and this is the first news that for me has raised concern. Not to be negative but if anyone has info as to how this might effect LDN distribution in Africa. Obviously it still seems like everything is in place and a go with Fidson. Maybe both LDN and antiretrovial and be used together for treatment?
I didn't realize there is an annual LDN conference.
https://www.ldnresearchtrust.org/conference/recorded-speakers-and-sessions
https://www.ldnresearchtrust.org/conference-2018/schedule
I'm always hopeful for news on Thursdays. Guess there is always next week.
Somebody bought 500K at 2 cents. Hopefully that's good for them!
I agree. There will not be enough buying interest to get this stock moving past whoever is selling noteholders most likely until revenue in Nigeria. When is that news coming?? Everyday around 9AM I take a look.